Résumé
Aim: Hyperinsulinemia is a constant feature of insulin resistant states. Insulin resistance appears to be a syndrome that is associated with type 2 diabetes mellitus, obesity, hypertension, lipid abnormalities and atherosclerotic cardiovascular disease. This study aimed at studying the effects of insulin suppression in hyperinsulinemic states regarding glucoregulation. Thirty patients were allocated in three groups: GIII: Obese nondiabetic [n =10], GIl: lean essential hypertensive patients [n =10], and Gill: obese type 2 diabetic patients [n =10]; together with 10 normal individuals as control. All cases were subjected to measurement of BMI, blood pressure, serum insulin and whole venous blood glucose fasting and after 60 minutes interval for 3 hours after 100 micro g subcutaneous injection of long acting somatostatin analogue. Fasting hyperinsulinemia was found in 80% of obese non-diabetics; 60% of lean essential hypertensive patients and in 90% of obese type 2 diabetic patients. Hyperinsulinem was positively correlated with the degree of BMI in group I and III. Maximal percentage suppression of insulin Was inversely correlated with BMI in the three different group. Blood glucose levels were significantly elevated in the second and third hours following somatostatin analogue injection in obese nondiabetic and lean hypertensive groups. Meanwhile it decreased significantly during the whole three hours in obese type 2 diabetic patients. Conclusions: One can conclude that suppression insulin by somatostatin analogue has significant effects on glucose regulation in patients with hyperinsulinemia. These effects were of dubious biological importance